DelistingApr 15, 2026, 04:36 PM
Alaunos Therapeutics Non-Compliant with Nasdaq Listing Rule
AI Summary
Alaunos Therapeutics, Inc. received a notice from Nasdaq on April 9, 2026, indicating non-compliance with Listing Rule 5550(b)(1). The company's stockholders' equity of $2,153,000, as reported in its 2025 Annual Report, falls below the required minimum of $2,500,000 for continued listing on the Nasdaq Capital Market. Additionally, the company does not meet alternative listing standards based on market value or net income. Alaunos Therapeutics plans to submit a compliance plan within 45 days, by May 26, 2026, to address the deficiency.
Key Highlights
- Received Nasdaq notice on April 9, 2026, for non-compliance.
- Stockholders' equity reported $2,153,000, below $2,500,000 minimum.
- Does not meet alternative listing standards of $35M market value or $500K net income.
- Company has 45 days (until May 26, 2026) to submit a compliance plan.
- Nasdaq may grant up to 180-day extension if plan is accepted.
Price Impact
More from TCRT